Lineage Cell Therapeutics, Inc.
LCTX
$1.25
-$0.06-4.58%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.24% | 24.05% | 76.43% | 19.42% | 6.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.24% | 24.05% | 76.43% | 19.42% | 6.19% |
| Cost of Revenue | 29.27% | 80.13% | 32.54% | 21.40% | 11.36% |
| Gross Profit | -3.22% | -399.93% | 2.45% | -23.65% | -17.58% |
| SG&A Expenses | 1.59% | 23.96% | 28.74% | 28.38% | 31.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.30% | 11.60% | 10.82% | 5.66% | 2.75% |
| Operating Income | -1.40% | -5.94% | 7.57% | -0.47% | -1.30% |
| Income Before Tax | -269.43% | -236.77% | -68.40% | 31.59% | 20.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -241.01% | -236.77% | -68.40% | 31.59% | 13.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -514.81% | -127.69% | -1,050.00% | -69.57% | -285.71% |
| Net Income | -241.41% | -236.42% | -69.14% | 31.49% | 13.39% |
| EBIT | -1.40% | -5.94% | 7.57% | -0.47% | -1.30% |
| EBITDA | -1.01% | -5.98% | 7.61% | -0.96% | -1.75% |
| EPS Basic | -189.79% | -169.28% | -35.07% | 41.64% | 22.83% |
| Normalized Basic EPS | -145.67% | -157.68% | -2.82% | 30.55% | 17.58% |
| EPS Diluted | -189.79% | -169.28% | -35.07% | 41.64% | 22.83% |
| Normalized Diluted EPS | -145.67% | -157.68% | -2.82% | 30.55% | 17.58% |
| Average Basic Shares Outstanding | 14.95% | 25.54% | 22.43% | 19.98% | 15.95% |
| Average Diluted Shares Outstanding | 14.95% | 25.54% | 22.43% | 19.98% | 15.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |